Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Die antimykotische Chemotherapie opportunistischer Pilzinfektionen

  • Conference paper
Pilzinfektionen bei abwehrgeschwächten Patienten

  • 26 Accesses

Zusammenfassung

Die Einführung von Itraconazol und Fluconazol brachte große Fortschritte in die Therapie opportunistischer Pilzinfektionen. Die Kliniker können heutzutage zwischen 5 verschiedenen systemisch wirksamen Antimykotika wählen, nämlich Amphotericin B (Amph B), liposomales Amphotericin B, 5-Flucytosin (5-FC), Itraconazol (ITRA) und Fluconazol (FLU). Die neuen Triazol-Derivate haben sich neben der Dermatologie und Gynäkologie bei folgenden opportunistischen Pilzinfektionen etabliert: die oropharyngeale und gastrointestinale Candidose spricht gut auf Fluconazol an [14,21]. Beide, Itraconazol [36, 38] und Fluconazol [32], werden erfolgreich bei der Erhaltungstherapie bei Cryptococcose bei AIDS-Patienten eingesetzt. Bei invasiver Aspergillose und beim Aspergillom erzielte ITRA in gewissen Fällen Heilungen, in anderen nicht [9,12, 36, 37]. Für beide Indikationen ist die klinische Prüfung noch nicht ganz abgeschlossen. Doch zeigt sich auch an diesem Horizont ein Lichtblick. Das liposomale Amph B wirkte in mehreren Fällen von therapieresistenten Pilzinfektionen kurativ [41]. Das ideale Antimykotikum zur Bekämpfung opportunistischer Pilzinfektionen existiert aber noch immer nicht. Es bleiben noch viele Probleme zu lösen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anaissie E, Wong E, Bodey GP, Obrien S, Gutterman J, Vadhan S (1989) Granulocyte-macrophage colony stimulating factor (GMCSF) plus amphotericin B (AmB) for disseminated (Diss.) mycoses in neutropenic cancer (Ca) patients (Pts). ICAAC Houston, Abstract No 73

    Google Scholar 

  2. Armstrong D (1989) Problems in the treatment of opportunistic fungal infections. In: Holmberg K and Mayer RD (Hrsg) Diagnosis and therapy of systemic fungal infections. Raven Press, New York, p 149–158

    Google Scholar 

  3. Armstrong D (1989) Problems in management of opportunistic fungal diseases. Rev Inf Dis ll(Suppl 7):S1591–S1599

    Article  Google Scholar 

  4. Baley JE, Kliegman RM, Fanaroff AA (1984) Disseminated fungal infections in very low birthweight infants: therapeutic toxicity. Pediatrics 73:153–157

    PubMed  CAS  Google Scholar 

  5. Bennet JE, Dismukes WE, Duma RJ et al. (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301 (3): 127–131

    Article  Google Scholar 

  6. Borelli D (1987) A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 9(Suppl 1):S57

    Article  PubMed  Google Scholar 

  7. Burch PA, Karp JE, Mery WG et al. (1987) Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 5:1985–1993

    PubMed  CAS  Google Scholar 

  8. Cheng IKP, Fang GX, Chan TM, Chan PCK, Chan MK (1989) Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Quart J Med, New Series 71, 265:407–416

    CAS  Google Scholar 

  9. Denning DW, Tucker RM, Hanson LH, Stevens DA (1989) Treatment of invasive aspergillosis with itraconazole. Am J Med 86:791–800

    Article  PubMed  CAS  Google Scholar 

  10. Dismukes WE, Cloud G, Gallis HA et al. (1987) Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317(6):334–341

    Article  PubMed  CAS  Google Scholar 

  11. Dupont B, Drouhet E (1985) Cutaneous, ocular, and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients. J Inf Dis 152:577–591

    Article  CAS  Google Scholar 

  12. Dupont B (1990) Itraconazole therapy in aspergillosis. J Acad Dermatol 23:607–614

    Article  CAS  Google Scholar 

  13. V Eiff M, Essink M, Roos N, Hiddermann W, Buechner Th, van de Loo J (1989) Hepatosplenic candidosis. Ztschr Antimikrob Antineoplast Chemother Suppl. 1:1

    Google Scholar 

  14. Hay RJ (1990) Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Inf Dis 12(Suppl 3):S334–S337

    Article  Google Scholar 

  15. Just-Nübling G, Laubenberger Ch, Helm EB, Falk S, Stille W (1990) Diagnose, klinischer Verlauf und Behandlung der Kryptokokken-Meningitis bei AIDS-Patienten. Forschg&Praxis 9:106

    Google Scholar 

  16. Larsen RA, Leal MAE, Chan LS (1990) Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Int Med 113:183–187

    PubMed  CAS  Google Scholar 

  17. Martino P, Meloni G, Cassone A (1990) Candidal endocarditis and treatment with fluconazole and granulocyte-macrophage colony-stimulating factor. Ann Int Med 112:966–967

    PubMed  CAS  Google Scholar 

  18. Matsumoto M, Matsubara S, Matsuno T, Tamura M, Hattori K, Nomura H, Ono M, Yokota T (1987) Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Inf&Immun 55:2715–2720

    CAS  Google Scholar 

  19. Meunier F, Klastersky J (1988) Recent developments in prophylaxis and therapy of invasive fungal infections in granulocytopenic cancer patients. Eur J Cancer Clin Oncol 24:539–544

    Article  PubMed  CAS  Google Scholar 

  20. Meunier F (1989) New methods for delivery of antifungal agents. Rev Inf Dis 11 (Suppl 7): 1605–1612

    Article  Google Scholar 

  21. Meunier F, Aoun M, Gerard M (1990) Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Rev Inf Dis 12(Suppl 3):S364-S368

    Article  Google Scholar 

  22. Polak A, Scholer HJ, Wall M (1982) Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemother 28:461–479

    Article  CAS  Google Scholar 

  23. Polak A (1983) Combined therapy of systemic mycoses. In: Spitzy KH, Karrer K (Hrsg) Proc 13th Intern Congr Chemother Vienna, H. Egermann, Symposia 49/1 and 49/2, part 20:2–9

    Google Scholar 

  24. Polak A (1987) Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemother 33:381–395

    Article  CAS  Google Scholar 

  25. Polak A (1988) Combination therapy with antifungal drugs. Mycoses 31 (Suppl 2):45–53

    PubMed  Google Scholar 

  26. Polak A (1989) Combination therapy for systemic mycosis. Infection 17:203–208

    Article  PubMed  CAS  Google Scholar 

  27. Polak A (1990) Combination therapy in systemic mycosis. J Chemother 2:211–217

    PubMed  CAS  Google Scholar 

  28. Robinson PA, Knirsch AK, Joseph JA (1990) Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Inf Dis 12(Suppl 3):S340-S365

    Article  Google Scholar 

  29. Schaffner A, Frick PG (1985) The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 151:902–920

    Article  PubMed  CAS  Google Scholar 

  30. Slingeneyer A, Laroche B, Stec F, Canaud B, Beraud JJ, Mion C (1984) Oral ketoconazole plus intraperitoneal 5-fluorocytosine as the sole treatment of fungal periotonitis (abstract). Perit Dial Bull 4(Suppl):S60

    Google Scholar 

  31. Stern JJ, Hartman BJ, Sharkey P, Rowland V, Squires KE, Murray HW, Graybill JR (1988) Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 85:477–480

    Article  PubMed  CAS  Google Scholar 

  32. Sugar AM, Sander D (1988) Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with Acquired Immunodeficiency Syndrome. Am J Med 85:481–489

    Article  PubMed  CAS  Google Scholar 

  33. Sugar AM, Stern JJ, Dupont B (1990) Overview: treatment of cryptococcal meningitis. Rev Inf Dis 12 (Suppl 3):S338-S348

    Article  Google Scholar 

  34. Thaler M, Bacher J, O’Leary T (1988) Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J Infect Dis 158:80–88

    Article  PubMed  CAS  Google Scholar 

  35. Tozzi V, Bordi E, Galgani S, Leoni GC, Narciso P, Sette P, Visco G (1989) Fluconazole treatment of cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 87:353

    Article  PubMed  CAS  Google Scholar 

  36. Viviani MA, Tortorano AM, Antonio P et al (1990) European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 23:587–593

    Article  PubMed  CAS  Google Scholar 

  37. Viviani MA, Tortorano AM, Woenstenborghs R, Cauwenbergh G (1988) Experience with itraconazole in deep mycoses in northern Italy. Mykosen 30:233–244

    Google Scholar 

  38. Walsh T, Pizzo PA (1989) Fungal infections in granulocytopenic patients: current approaches to classification, diagnosis and treatment. In: Holmberg K, Meyer RD (Hrsg) Diagnosis and Therapy of Systemic Fungal Infections. Raven Press, New York, p 47–70

    Google Scholar 

  39. Walsh TJ, Pizzo A (1988) Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 7:460–475

    Article  PubMed  CAS  Google Scholar 

  40. Yasuda H, Ajiki Y, Shimozato T, Kasahara M, Kawada H, Iwata M, Shimizu K (1990) Therapeutic efficacy of granulocyte colony-stimulating factor alone and in combination with antibiotics against Pseudomonas aeruginosa infections in mice. Infect and Immun 58:2502–2509

    CAS  Google Scholar 

  41. ICAAC Atlanta 1990. Abstracts

    Google Scholar 

Download references

Authors
  1. A. Polak
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert Koch-Institut, Bundesgesundheitsamt, Nordufer 20, W-1000, Berlin 65, Deutschland

    F. Staib

  2. Standort Charlottenburg, Abteilung Innere Medizin und Poliklinik, Universitätsklinikum Rudolf Virchow, Spandauer Damm 130, W-1000, Berlin 19, Deutschland

    D. Huhn

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Polak, A. (1991). Die antimykotische Chemotherapie opportunistischer Pilzinfektionen. In: Staib, F., Huhn, D. (eds) Pilzinfektionen bei abwehrgeschwächten Patienten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76845-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76845-3_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-54391-6

  • Online ISBN: 978-3-642-76845-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation